nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCB1—ovarian cancer	0.177	1	CbGaD
Dabrafenib—SLCO1B3—Paclitaxel—ovarian cancer	0.0736	0.169	CbGbCtD
Dabrafenib—ABCG2—Topotecan—ovarian cancer	0.0688	0.158	CbGbCtD
Dabrafenib—SLCO1B3—Docetaxel—ovarian cancer	0.0532	0.122	CbGbCtD
Dabrafenib—ABCG2—Paclitaxel—ovarian cancer	0.0341	0.0783	CbGbCtD
Dabrafenib—ABCG2—Carboplatin—ovarian cancer	0.032	0.0737	CbGbCtD
Dabrafenib—ABCB1—Topotecan—ovarian cancer	0.0248	0.057	CbGbCtD
Dabrafenib—ABCG2—Docetaxel—ovarian cancer	0.0246	0.0566	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—ovarian cancer	0.0184	0.0422	CbGbCtD
Dabrafenib—CYP2C8—Paclitaxel—ovarian cancer	0.0181	0.0417	CbGbCtD
Dabrafenib—ABCB1—Vinorelbine—ovarian cancer	0.0175	0.0402	CbGbCtD
Dabrafenib—CYP3A4—Topotecan—ovarian cancer	0.0149	0.0342	CbGbCtD
Dabrafenib—ABCB1—Paclitaxel—ovarian cancer	0.0123	0.0282	CbGbCtD
Dabrafenib—CYP3A4—Vinorelbine—ovarian cancer	0.0105	0.0241	CbGbCtD
Dabrafenib—ABCB1—Docetaxel—ovarian cancer	0.00888	0.0204	CbGbCtD
Dabrafenib—CYP3A4—Paclitaxel—ovarian cancer	0.00736	0.0169	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—ovarian cancer	0.00662	0.0152	CbGbCtD
Dabrafenib—CYP3A4—Docetaxel—ovarian cancer	0.00532	0.0122	CbGbCtD
Dabrafenib—NEK11—uterine cervix—ovarian cancer	0.00457	0.0579	CbGeAlD
Dabrafenib—CYP3A4—Doxorubicin—ovarian cancer	0.00396	0.00912	CbGbCtD
Dabrafenib—NEK11—uterus—ovarian cancer	0.00381	0.0482	CbGeAlD
Dabrafenib—NEK11—female reproductive system—ovarian cancer	0.00342	0.0433	CbGeAlD
Dabrafenib—LIMK1—decidua—ovarian cancer	0.00312	0.0394	CbGeAlD
Dabrafenib—NEK11—female gonad—ovarian cancer	0.00312	0.0394	CbGeAlD
Dabrafenib—NEK11—testis—ovarian cancer	0.00276	0.035	CbGeAlD
Dabrafenib—LIMK1—vagina—ovarian cancer	0.00222	0.0281	CbGeAlD
Dabrafenib—NEK11—lymph node—ovarian cancer	0.002	0.0254	CbGeAlD
Dabrafenib—LIMK1—testis—ovarian cancer	0.00198	0.025	CbGeAlD
Dabrafenib—BRAF—endometrium—ovarian cancer	0.00183	0.0231	CbGeAlD
Dabrafenib—RAF1—myometrium—ovarian cancer	0.00173	0.0219	CbGeAlD
Dabrafenib—SIK1—uterine cervix—ovarian cancer	0.00169	0.0214	CbGeAlD
Dabrafenib—BRAF—uterus—ovarian cancer	0.00168	0.0213	CbGeAlD
Dabrafenib—RAF1—embryo—ovarian cancer	0.00166	0.0211	CbGeAlD
Dabrafenib—SIK1—decidua—ovarian cancer	0.00161	0.0204	CbGeAlD
Dabrafenib—SIK1—endometrium—ovarian cancer	0.00153	0.0194	CbGeAlD
Dabrafenib—LIMK1—lymph node—ovarian cancer	0.00143	0.0181	CbGeAlD
Dabrafenib—BRAF—bone marrow—ovarian cancer	0.00143	0.0181	CbGeAlD
Dabrafenib—SIK1—gonad—ovarian cancer	0.00142	0.018	CbGeAlD
Dabrafenib—SIK1—uterus—ovarian cancer	0.00141	0.0178	CbGeAlD
Dabrafenib—BRAF—female gonad—ovarian cancer	0.00138	0.0174	CbGeAlD
Dabrafenib—BRAF—vagina—ovarian cancer	0.00137	0.0173	CbGeAlD
Dabrafenib—RAF1—epithelium—ovarian cancer	0.00136	0.0172	CbGeAlD
Dabrafenib—RAF1—uterine cervix—ovarian cancer	0.00135	0.017	CbGeAlD
Dabrafenib—RAF1—decidua—ovarian cancer	0.00128	0.0162	CbGeAlD
Dabrafenib—SIK1—female reproductive system—ovarian cancer	0.00127	0.016	CbGeAlD
Dabrafenib—BRAF—testis—ovarian cancer	0.00122	0.0155	CbGeAlD
Dabrafenib—RAF1—endometrium—ovarian cancer	0.00122	0.0154	CbGeAlD
Dabrafenib—SIK1—bone marrow—ovarian cancer	0.0012	0.0151	CbGeAlD
Dabrafenib—SLCO1B3—vagina—ovarian cancer	0.00118	0.0149	CbGeAlD
Dabrafenib—SIK1—female gonad—ovarian cancer	0.00115	0.0146	CbGeAlD
Dabrafenib—RAF1—gonad—ovarian cancer	0.00113	0.0143	CbGeAlD
Dabrafenib—RAF1—uterus—ovarian cancer	0.00112	0.0142	CbGeAlD
Dabrafenib—SIK1—testis—ovarian cancer	0.00102	0.0129	CbGeAlD
Dabrafenib—RAF1—female reproductive system—ovarian cancer	0.00101	0.0128	CbGeAlD
Dabrafenib—RAF1—bone marrow—ovarian cancer	0.000952	0.0121	CbGeAlD
Dabrafenib—RAF1—female gonad—ovarian cancer	0.000918	0.0116	CbGeAlD
Dabrafenib—RAF1—vagina—ovarian cancer	0.000912	0.0115	CbGeAlD
Dabrafenib—BRAF—lymph node—ovarian cancer	0.000886	0.0112	CbGeAlD
Dabrafenib—RAF1—testis—ovarian cancer	0.000814	0.0103	CbGeAlD
Dabrafenib—SLCO1B1—female reproductive system—ovarian cancer	0.000755	0.00955	CbGeAlD
Dabrafenib—SIK1—lymph node—ovarian cancer	0.000741	0.00938	CbGeAlD
Dabrafenib—ABCG2—myometrium—ovarian cancer	0.000716	0.00906	CbGeAlD
Dabrafenib—RAF1—lymph node—ovarian cancer	0.00059	0.00747	CbGeAlD
Dabrafenib—ABCG2—uterine cervix—ovarian cancer	0.000557	0.00705	CbGeAlD
Dabrafenib—ABCG2—decidua—ovarian cancer	0.000531	0.00672	CbGeAlD
Dabrafenib—CYP2C8—endometrium—ovarian cancer	0.000518	0.00656	CbGeAlD
Dabrafenib—ABCG2—endometrium—ovarian cancer	0.000504	0.00638	CbGeAlD
Dabrafenib—ABCG2—uterus—ovarian cancer	0.000464	0.00588	CbGeAlD
Dabrafenib—CYP2C8—female reproductive system—ovarian cancer	0.000429	0.00543	CbGeAlD
Dabrafenib—ABCG2—bone marrow—ovarian cancer	0.000394	0.00499	CbGeAlD
Dabrafenib—CYP2C8—vagina—ovarian cancer	0.000388	0.00491	CbGeAlD
Dabrafenib—ABCG2—female gonad—ovarian cancer	0.00038	0.00481	CbGeAlD
Dabrafenib—ABCG2—vagina—ovarian cancer	0.000377	0.00478	CbGeAlD
Dabrafenib—ABCB1—myometrium—ovarian cancer	0.000353	0.00447	CbGeAlD
Dabrafenib—CYP2C8—testis—ovarian cancer	0.000346	0.00438	CbGeAlD
Dabrafenib—ABCB1—embryo—ovarian cancer	0.000339	0.0043	CbGeAlD
Dabrafenib—ABCG2—testis—ovarian cancer	0.000337	0.00426	CbGeAlD
Dabrafenib—CYP3A4—female reproductive system—ovarian cancer	0.000291	0.00368	CbGeAlD
Dabrafenib—ABCB1—epithelium—ovarian cancer	0.000277	0.00351	CbGeAlD
Dabrafenib—ABCB1—uterine cervix—ovarian cancer	0.000275	0.00348	CbGeAlD
Dabrafenib—ABCB1—decidua—ovarian cancer	0.000262	0.00331	CbGeAlD
Dabrafenib—ABCB1—endometrium—ovarian cancer	0.000248	0.00314	CbGeAlD
Dabrafenib—ABCG2—lymph node—ovarian cancer	0.000244	0.00309	CbGeAlD
Dabrafenib—ABCB1—gonad—ovarian cancer	0.00023	0.00292	CbGeAlD
Dabrafenib—ABCB1—uterus—ovarian cancer	0.000229	0.0029	CbGeAlD
Dabrafenib—ABCB1—female reproductive system—ovarian cancer	0.000206	0.0026	CbGeAlD
Dabrafenib—ABCB1—bone marrow—ovarian cancer	0.000194	0.00246	CbGeAlD
Dabrafenib—ABCB1—female gonad—ovarian cancer	0.000187	0.00237	CbGeAlD
Dabrafenib—ABCB1—vagina—ovarian cancer	0.000186	0.00236	CbGeAlD
Dabrafenib—ABCB1—testis—ovarian cancer	0.000166	0.0021	CbGeAlD
Dabrafenib—Hyponatraemia—Epirubicin—ovarian cancer	0.000161	0.00103	CcSEcCtD
Dabrafenib—Renal failure acute—Doxorubicin—ovarian cancer	0.000161	0.00102	CcSEcCtD
Dabrafenib—Diarrhoea—Melphalan—ovarian cancer	0.000161	0.00102	CcSEcCtD
Dabrafenib—Pain in extremity—Epirubicin—ovarian cancer	0.000161	0.00102	CcSEcCtD
Dabrafenib—Nausea—Chlorambucil—ovarian cancer	0.00016	0.00102	CcSEcCtD
Dabrafenib—Vision blurred—Paclitaxel—ovarian cancer	0.000159	0.00102	CcSEcCtD
Dabrafenib—Dizziness—Topotecan—ovarian cancer	0.000159	0.00101	CcSEcCtD
Dabrafenib—Anaemia—Paclitaxel—ovarian cancer	0.000156	0.000996	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—ovarian cancer	0.000156	0.00099	CcSEcCtD
Dabrafenib—Eye disorder—Docetaxel—ovarian cancer	0.000154	0.00098	CcSEcCtD
Dabrafenib—Vomiting—Topotecan—ovarian cancer	0.000153	0.000971	CcSEcCtD
Dabrafenib—Leukopenia—Paclitaxel—ovarian cancer	0.000151	0.000964	CcSEcCtD
Dabrafenib—Rash—Topotecan—ovarian cancer	0.000151	0.000963	CcSEcCtD
Dabrafenib—Hypersensitivity—Vinorelbine—ovarian cancer	0.000151	0.000963	CcSEcCtD
Dabrafenib—Dermatitis—Topotecan—ovarian cancer	0.000151	0.000962	CcSEcCtD
Dabrafenib—Blood creatinine increased—Epirubicin—ovarian cancer	0.00015	0.000958	CcSEcCtD
Dabrafenib—Headache—Topotecan—ovarian cancer	0.00015	0.000957	CcSEcCtD
Dabrafenib—Angiopathy—Docetaxel—ovarian cancer	0.000149	0.000952	CcSEcCtD
Dabrafenib—Vomiting—Melphalan—ovarian cancer	0.000149	0.000951	CcSEcCtD
Dabrafenib—Dehydration—Epirubicin—ovarian cancer	0.000149	0.000951	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—ovarian cancer	0.000149	0.00095	CcSEcCtD
Dabrafenib—Immune system disorder—Docetaxel—ovarian cancer	0.000149	0.000947	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—ovarian cancer	0.000149	0.000946	CcSEcCtD
Dabrafenib—Mediastinal disorder—Docetaxel—ovarian cancer	0.000148	0.000945	CcSEcCtD
Dabrafenib—Rash—Melphalan—ovarian cancer	0.000148	0.000943	CcSEcCtD
Dabrafenib—Dermatitis—Melphalan—ovarian cancer	0.000148	0.000942	CcSEcCtD
Dabrafenib—Chills—Docetaxel—ovarian cancer	0.000148	0.000941	CcSEcCtD
Dabrafenib—Cough—Paclitaxel—ovarian cancer	0.000148	0.00094	CcSEcCtD
Dabrafenib—Asthenia—Vinorelbine—ovarian cancer	0.000147	0.000938	CcSEcCtD
Dabrafenib—Dry skin—Epirubicin—ovarian cancer	0.000147	0.000937	CcSEcCtD
Dabrafenib—Arrhythmia—Docetaxel—ovarian cancer	0.000147	0.000937	CcSEcCtD
Dabrafenib—Abdominal pain upper—Epirubicin—ovarian cancer	0.000147	0.000934	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—ovarian cancer	0.000146	0.000931	CcSEcCtD
Dabrafenib—Hypertension—Paclitaxel—ovarian cancer	0.000146	0.00093	CcSEcCtD
Dabrafenib—Alopecia—Docetaxel—ovarian cancer	0.000146	0.000927	CcSEcCtD
Dabrafenib—Pruritus—Vinorelbine—ovarian cancer	0.000145	0.000925	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000145	0.000921	CcSEcCtD
Dabrafenib—Mental disorder—Docetaxel—ovarian cancer	0.000144	0.000919	CcSEcCtD
Dabrafenib—Arthralgia—Paclitaxel—ovarian cancer	0.000144	0.000917	CcSEcCtD
Dabrafenib—Myalgia—Paclitaxel—ovarian cancer	0.000144	0.000917	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—ovarian cancer	0.000144	0.000914	CcSEcCtD
Dabrafenib—Erythema—Docetaxel—ovarian cancer	0.000143	0.000913	CcSEcCtD
Dabrafenib—Malnutrition—Docetaxel—ovarian cancer	0.000143	0.000913	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000143	0.000911	CcSEcCtD
Dabrafenib—Nausea—Topotecan—ovarian cancer	0.000143	0.000908	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000142	0.000902	CcSEcCtD
Dabrafenib—Dry mouth—Paclitaxel—ovarian cancer	0.000141	0.000897	CcSEcCtD
Dabrafenib—Diarrhoea—Vinorelbine—ovarian cancer	0.00014	0.000894	CcSEcCtD
Dabrafenib—Nausea—Melphalan—ovarian cancer	0.00014	0.000889	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000139	0.000886	CcSEcCtD
Dabrafenib—Back pain—Docetaxel—ovarian cancer	0.000139	0.000883	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—ovarian cancer	0.000138	0.00088	CcSEcCtD
Dabrafenib—Oedema—Paclitaxel—ovarian cancer	0.000138	0.000879	CcSEcCtD
Dabrafenib—Muscle spasms—Docetaxel—ovarian cancer	0.000138	0.000878	CcSEcCtD
Dabrafenib—Infection—Paclitaxel—ovarian cancer	0.000137	0.000873	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—ovarian cancer	0.000136	0.000867	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—ovarian cancer	0.000136	0.000867	CcSEcCtD
Dabrafenib—Dizziness—Vinorelbine—ovarian cancer	0.000136	0.000864	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000136	0.000864	CcSEcCtD
Dabrafenib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000135	0.000862	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—ovarian cancer	0.000135	0.000861	CcSEcCtD
Dabrafenib—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000135	0.000861	CcSEcCtD
Dabrafenib—Skin disorder—Paclitaxel—ovarian cancer	0.000134	0.000854	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000134	0.000852	CcSEcCtD
Dabrafenib—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000133	0.00085	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000133	0.000846	CcSEcCtD
Dabrafenib—Anaemia—Docetaxel—ovarian cancer	0.000133	0.000844	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000131	0.000835	CcSEcCtD
Dabrafenib—Vomiting—Vinorelbine—ovarian cancer	0.000131	0.000831	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—ovarian cancer	0.00013	0.000826	CcSEcCtD
Dabrafenib—Rash—Vinorelbine—ovarian cancer	0.000129	0.000824	CcSEcCtD
Dabrafenib—Dermatitis—Vinorelbine—ovarian cancer	0.000129	0.000823	CcSEcCtD
Dabrafenib—Hypotension—Paclitaxel—ovarian cancer	0.000129	0.000821	CcSEcCtD
Dabrafenib—Headache—Vinorelbine—ovarian cancer	0.000129	0.000819	CcSEcCtD
Dabrafenib—Leukopenia—Docetaxel—ovarian cancer	0.000128	0.000817	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—ovarian cancer	0.000126	0.000802	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000126	0.000801	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—ovarian cancer	0.000125	0.000797	CcSEcCtD
Dabrafenib—Cough—Docetaxel—ovarian cancer	0.000125	0.000797	CcSEcCtD
Dabrafenib—Insomnia—Paclitaxel—ovarian cancer	0.000125	0.000795	CcSEcCtD
Dabrafenib—Hypertension—Docetaxel—ovarian cancer	0.000124	0.000788	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—ovarian cancer	0.000124	0.000788	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—ovarian cancer	0.000124	0.000788	CcSEcCtD
Dabrafenib—Arthralgia—Docetaxel—ovarian cancer	0.000122	0.000777	CcSEcCtD
Dabrafenib—Myalgia—Docetaxel—ovarian cancer	0.000122	0.000777	CcSEcCtD
Dabrafenib—Nausea—Vinorelbine—ovarian cancer	0.000122	0.000776	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—ovarian cancer	0.000122	0.000775	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000121	0.000772	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—ovarian cancer	0.000121	0.000768	CcSEcCtD
Dabrafenib—ABCB1—lymph node—ovarian cancer	0.00012	0.00152	CbGeAlD
Dabrafenib—Urinary tract infection—Epirubicin—ovarian cancer	0.00012	0.000766	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—ovarian cancer	0.00012	0.000765	CcSEcCtD
Dabrafenib—Decreased appetite—Paclitaxel—ovarian cancer	0.00012	0.000764	CcSEcCtD
Dabrafenib—Dry mouth—Docetaxel—ovarian cancer	0.000119	0.00076	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000119	0.000759	CcSEcCtD
Dabrafenib—Fatigue—Paclitaxel—ovarian cancer	0.000119	0.000758	CcSEcCtD
Dabrafenib—Constipation—Paclitaxel—ovarian cancer	0.000118	0.000752	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—ovarian cancer	0.000118	0.000751	CcSEcCtD
Dabrafenib—Oedema—Docetaxel—ovarian cancer	0.000117	0.000745	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—ovarian cancer	0.000117	0.000743	CcSEcCtD
Dabrafenib—Infection—Docetaxel—ovarian cancer	0.000116	0.00074	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000116	0.000738	CcSEcCtD
Dabrafenib—Nervous system disorder—Docetaxel—ovarian cancer	0.000115	0.000731	CcSEcCtD
Dabrafenib—Thrombocytopenia—Docetaxel—ovarian cancer	0.000115	0.00073	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—ovarian cancer	0.000115	0.000729	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—ovarian cancer	0.000115	0.000729	CcSEcCtD
Dabrafenib—Skin disorder—Docetaxel—ovarian cancer	0.000114	0.000724	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000113	0.000719	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—ovarian cancer	0.000113	0.000717	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—ovarian cancer	0.000112	0.000711	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—ovarian cancer	0.000112	0.000711	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—ovarian cancer	0.000111	0.000709	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—ovarian cancer	0.000111	0.000707	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—ovarian cancer	0.00011	0.000699	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—ovarian cancer	0.000109	0.000697	CcSEcCtD
Dabrafenib—Hypotension—Docetaxel—ovarian cancer	0.000109	0.000696	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—ovarian cancer	0.000109	0.000695	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—ovarian cancer	0.000109	0.000695	CcSEcCtD
Dabrafenib—Body temperature increased—Paclitaxel—ovarian cancer	0.000109	0.000695	CcSEcCtD
Dabrafenib—Abdominal pain—Paclitaxel—ovarian cancer	0.000109	0.000695	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—ovarian cancer	0.000109	0.000693	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—ovarian cancer	0.000108	0.000688	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000107	0.000679	CcSEcCtD
Dabrafenib—Insomnia—Docetaxel—ovarian cancer	0.000106	0.000674	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—ovarian cancer	0.000104	0.000661	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—ovarian cancer	0.000103	0.000658	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—ovarian cancer	0.000103	0.000655	CcSEcCtD
Dabrafenib—Decreased appetite—Docetaxel—ovarian cancer	0.000102	0.000648	CcSEcCtD
Dabrafenib—Hypersensitivity—Paclitaxel—ovarian cancer	0.000102	0.000648	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000102	0.000646	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—ovarian cancer	0.000101	0.000645	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000101	0.000643	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000101	0.000643	CcSEcCtD
Dabrafenib—Fatigue—Docetaxel—ovarian cancer	0.000101	0.000642	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—ovarian cancer	0.000101	0.000642	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—ovarian cancer	0.000101	0.000642	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—ovarian cancer	0.0001	0.000639	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—ovarian cancer	0.0001	0.000638	CcSEcCtD
Dabrafenib—Constipation—Docetaxel—ovarian cancer	0.0001	0.000637	CcSEcCtD
Dabrafenib—Chills—Epirubicin—ovarian cancer	9.97e-05	0.000635	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—ovarian cancer	9.93e-05	0.000632	CcSEcCtD
Dabrafenib—Asthenia—Paclitaxel—ovarian cancer	9.91e-05	0.000631	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—ovarian cancer	9.82e-05	0.000625	CcSEcCtD
Dabrafenib—Pruritus—Paclitaxel—ovarian cancer	9.77e-05	0.000622	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—ovarian cancer	9.74e-05	0.00062	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—ovarian cancer	9.67e-05	0.000616	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—ovarian cancer	9.67e-05	0.000616	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—ovarian cancer	9.61e-05	0.000612	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Docetaxel—ovarian cancer	9.57e-05	0.000609	CcSEcCtD
Dabrafenib—Diarrhoea—Paclitaxel—ovarian cancer	9.45e-05	0.000602	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—ovarian cancer	9.36e-05	0.000596	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—ovarian cancer	9.33e-05	0.000594	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—ovarian cancer	9.3e-05	0.000592	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—ovarian cancer	9.29e-05	0.000591	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—ovarian cancer	9.27e-05	0.00059	CcSEcCtD
Dabrafenib—Body temperature increased—Docetaxel—ovarian cancer	9.25e-05	0.000589	CcSEcCtD
Dabrafenib—Abdominal pain—Docetaxel—ovarian cancer	9.25e-05	0.000589	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—ovarian cancer	9.23e-05	0.000587	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—ovarian cancer	9.18e-05	0.000585	CcSEcCtD
Dabrafenib—Dizziness—Paclitaxel—ovarian cancer	9.13e-05	0.000581	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—ovarian cancer	9.12e-05	0.00058	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—ovarian cancer	9.09e-05	0.000578	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—ovarian cancer	9.01e-05	0.000573	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—ovarian cancer	8.95e-05	0.00057	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—ovarian cancer	8.95e-05	0.00057	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—ovarian cancer	8.94e-05	0.000569	CcSEcCtD
Dabrafenib—Vomiting—Paclitaxel—ovarian cancer	8.78e-05	0.000559	CcSEcCtD
Dabrafenib—Rash—Paclitaxel—ovarian cancer	8.71e-05	0.000554	CcSEcCtD
Dabrafenib—Dermatitis—Paclitaxel—ovarian cancer	8.7e-05	0.000554	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—ovarian cancer	8.66e-05	0.000551	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—ovarian cancer	8.66e-05	0.000551	CcSEcCtD
Dabrafenib—Headache—Paclitaxel—ovarian cancer	8.65e-05	0.000551	CcSEcCtD
Dabrafenib—Hypersensitivity—Docetaxel—ovarian cancer	8.62e-05	0.000549	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—ovarian cancer	8.61e-05	0.000548	CcSEcCtD
Dabrafenib—Cough—Epirubicin—ovarian cancer	8.44e-05	0.000537	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—ovarian cancer	8.44e-05	0.000537	CcSEcCtD
Dabrafenib—Asthenia—Docetaxel—ovarian cancer	8.4e-05	0.000535	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—ovarian cancer	8.35e-05	0.000532	CcSEcCtD
Dabrafenib—Pruritus—Docetaxel—ovarian cancer	8.28e-05	0.000527	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—ovarian cancer	8.27e-05	0.000527	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—ovarian cancer	8.24e-05	0.000524	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—ovarian cancer	8.24e-05	0.000524	CcSEcCtD
Dabrafenib—Nausea—Paclitaxel—ovarian cancer	8.2e-05	0.000522	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	8.18e-05	0.000521	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—ovarian cancer	8.05e-05	0.000513	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—ovarian cancer	8.01e-05	0.00051	CcSEcCtD
Dabrafenib—Diarrhoea—Docetaxel—ovarian cancer	8.01e-05	0.00051	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—ovarian cancer	7.89e-05	0.000503	CcSEcCtD
Dabrafenib—Infection—Epirubicin—ovarian cancer	7.84e-05	0.000499	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—ovarian cancer	7.81e-05	0.000497	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—ovarian cancer	7.74e-05	0.000493	CcSEcCtD
Dabrafenib—Dizziness—Docetaxel—ovarian cancer	7.74e-05	0.000493	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—ovarian cancer	7.73e-05	0.000492	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—ovarian cancer	7.73e-05	0.000492	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—ovarian cancer	7.67e-05	0.000488	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—ovarian cancer	7.63e-05	0.000486	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—ovarian cancer	7.62e-05	0.000485	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—ovarian cancer	7.62e-05	0.000485	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	7.57e-05	0.000482	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—ovarian cancer	7.45e-05	0.000474	CcSEcCtD
Dabrafenib—Vomiting—Docetaxel—ovarian cancer	7.44e-05	0.000474	CcSEcCtD
Dabrafenib—Rash—Docetaxel—ovarian cancer	7.38e-05	0.00047	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—ovarian cancer	7.38e-05	0.00047	CcSEcCtD
Dabrafenib—Dermatitis—Docetaxel—ovarian cancer	7.37e-05	0.000469	CcSEcCtD
Dabrafenib—Headache—Docetaxel—ovarian cancer	7.33e-05	0.000467	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—ovarian cancer	7.3e-05	0.000465	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—ovarian cancer	7.26e-05	0.000462	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	7.19e-05	0.000458	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—ovarian cancer	7.16e-05	0.000456	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—ovarian cancer	7.15e-05	0.000455	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—ovarian cancer	7.14e-05	0.000455	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—ovarian cancer	7.1e-05	0.000452	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—ovarian cancer	7.06e-05	0.00045	CcSEcCtD
Dabrafenib—Nausea—Docetaxel—ovarian cancer	6.95e-05	0.000443	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—ovarian cancer	6.86e-05	0.000437	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—ovarian cancer	6.83e-05	0.000435	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.82e-05	0.000434	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—ovarian cancer	6.81e-05	0.000433	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—ovarian cancer	6.75e-05	0.00043	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.66e-05	0.000424	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—ovarian cancer	6.61e-05	0.000421	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—ovarian cancer	6.46e-05	0.000411	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—ovarian cancer	6.35e-05	0.000404	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	6.31e-05	0.000401	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—ovarian cancer	6.3e-05	0.000401	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—ovarian cancer	6.25e-05	0.000398	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—ovarian cancer	6.24e-05	0.000397	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—ovarian cancer	6.24e-05	0.000397	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.97e-05	0.00038	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—ovarian cancer	5.82e-05	0.00037	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—ovarian cancer	5.77e-05	0.000368	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—ovarian cancer	5.77e-05	0.000368	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—ovarian cancer	5.66e-05	0.000361	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—ovarian cancer	5.59e-05	0.000356	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—ovarian cancer	5.4e-05	0.000344	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—ovarian cancer	5.38e-05	0.000343	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—ovarian cancer	5.24e-05	0.000334	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—ovarian cancer	5.22e-05	0.000332	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—ovarian cancer	5.17e-05	0.000329	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—ovarian cancer	5.02e-05	0.00032	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—ovarian cancer	5e-05	0.000318	CcSEcCtD
Dabrafenib—Rash—Epirubicin—ovarian cancer	4.98e-05	0.000317	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—ovarian cancer	4.97e-05	0.000317	CcSEcCtD
Dabrafenib—Headache—Epirubicin—ovarian cancer	4.95e-05	0.000315	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—ovarian cancer	4.83e-05	0.000308	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—ovarian cancer	4.69e-05	0.000299	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—ovarian cancer	4.64e-05	0.000296	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—ovarian cancer	4.61e-05	0.000293	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—ovarian cancer	4.6e-05	0.000293	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—ovarian cancer	4.58e-05	0.000291	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—ovarian cancer	4.34e-05	0.000276	CcSEcCtD
Dabrafenib—SLCO1B1—Metabolism—PPP2R1A—ovarian cancer	1.03e-05	6.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—ovarian cancer	1.03e-05	6.73e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CG—ovarian cancer	1.03e-05	6.72e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.02e-05	6.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—MAPK3—ovarian cancer	1.02e-05	6.69e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.02e-05	6.68e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	9.98e-06	6.54e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	9.98e-06	6.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MAPK1—ovarian cancer	9.89e-06	6.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—ovarian cancer	9.89e-06	6.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6ST—ovarian cancer	9.84e-06	6.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB2—ovarian cancer	9.8e-06	6.42e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.76e-06	6.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—MAPK1—ovarian cancer	9.71e-06	6.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CAV1—ovarian cancer	9.7e-06	6.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CB—ovarian cancer	9.67e-06	6.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTOR—ovarian cancer	9.67e-06	6.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NRAS—ovarian cancer	9.59e-06	6.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CAV1—ovarian cancer	9.58e-06	6.28e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCB1—ovarian cancer	9.55e-06	6.26e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPP2R1A—ovarian cancer	9.53e-06	6.24e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	9.43e-06	6.18e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TYMS—ovarian cancer	9.38e-06	6.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ESR1—ovarian cancer	9.35e-06	6.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—ovarian cancer	9.35e-06	6.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRAS—ovarian cancer	9.21e-06	6.03e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6ST—ovarian cancer	9.2e-06	6.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK3—ovarian cancer	9.18e-06	6.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—ovarian cancer	9.17e-06	6.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PPP2R1A—ovarian cancer	9.13e-06	5.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CD—ovarian cancer	9.1e-06	5.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6ST—ovarian cancer	9.09e-06	5.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1B—ovarian cancer	9.07e-06	5.95e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CD—ovarian cancer	9.01e-06	5.91e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—YAP1—ovarian cancer	8.98e-06	5.88e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.89e-06	5.82e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCB1—ovarian cancer	8.85e-06	5.8e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CG—ovarian cancer	8.84e-06	5.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APC—ovarian cancer	8.84e-06	5.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK1—ovarian cancer	8.74e-06	5.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—ovarian cancer	8.74e-06	5.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APC—ovarian cancer	8.73e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDH1—ovarian cancer	8.7e-06	5.7e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TYMS—ovarian cancer	8.69e-06	5.69e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	8.66e-06	5.67e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—ovarian cancer	8.57e-06	5.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CA—ovarian cancer	8.42e-06	5.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—ovarian cancer	8.39e-06	5.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	8.38e-06	5.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTEN—ovarian cancer	8.35e-06	5.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CD—ovarian cancer	8.31e-06	5.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—ovarian cancer	8.25e-06	5.41e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYTB—ovarian cancer	8.22e-06	5.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—ovarian cancer	8.15e-06	5.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—ovarian cancer	7.94e-06	5.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CB—ovarian cancer	7.93e-06	5.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—ovarian cancer	7.93e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CB—ovarian cancer	7.85e-06	5.15e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—YAP1—ovarian cancer	7.82e-06	5.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.81e-06	5.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—ovarian cancer	7.79e-06	5.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CD—ovarian cancer	7.77e-06	5.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CD—ovarian cancer	7.67e-06	5.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—ovarian cancer	7.62e-06	4.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—ovarian cancer	7.6e-06	4.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—ovarian cancer	7.58e-06	4.97e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CAV1—ovarian cancer	7.56e-06	4.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—ovarian cancer	7.47e-06	4.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—ovarian cancer	7.45e-06	4.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—ovarian cancer	7.34e-06	4.81e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—FASN—ovarian cancer	7.32e-06	4.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—ovarian cancer	7.28e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—ovarian cancer	7.28e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—ovarian cancer	7.26e-06	4.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MTOR—ovarian cancer	7.25e-06	4.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CB—ovarian cancer	7.25e-06	4.75e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.22e-06	4.73e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC5A5—ovarian cancer	7.2e-06	4.72e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPP1CC—ovarian cancer	7.19e-06	4.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BRIP1—ovarian cancer	7.19e-06	4.71e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK3—ovarian cancer	7.14e-06	4.68e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	7.07e-06	4.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—ovarian cancer	7.02e-06	4.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—ovarian cancer	7.01e-06	4.6e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAV1—ovarian cancer	7e-06	4.59e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A1—ovarian cancer	6.95e-06	4.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—ovarian cancer	6.94e-06	4.55e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—ovarian cancer	6.89e-06	4.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—ovarian cancer	6.88e-06	4.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—ovarian cancer	6.86e-06	4.5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.81e-06	4.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1B—ovarian cancer	6.8e-06	4.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK1—ovarian cancer	6.79e-06	4.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—ovarian cancer	6.79e-06	4.45e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—ovarian cancer	6.79e-06	4.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—ovarian cancer	6.78e-06	4.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MTOR—ovarian cancer	6.77e-06	4.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CB—ovarian cancer	6.77e-06	4.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—ovarian cancer	6.74e-06	4.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—ovarian cancer	6.71e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CAV1—ovarian cancer	6.71e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—ovarian cancer	6.69e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTOR—ovarian cancer	6.69e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1B1—ovarian cancer	6.67e-06	4.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—ovarian cancer	6.65e-06	4.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—ovarian cancer	6.51e-06	4.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—ovarian cancer	6.47e-06	4.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—ovarian cancer	6.42e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—ovarian cancer	6.42e-06	4.2e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FASN—ovarian cancer	6.38e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—ovarian cancer	6.38e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6ST—ovarian cancer	6.36e-06	4.17e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—ovarian cancer	6.35e-06	4.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—ovarian cancer	6.28e-06	4.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A5—ovarian cancer	6.27e-06	4.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—ovarian cancer	6.26e-06	4.1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—ovarian cancer	6.23e-06	4.08e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—ovarian cancer	6.22e-06	4.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—ovarian cancer	6.19e-06	4.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—ovarian cancer	6.11e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—ovarian cancer	6.11e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—ovarian cancer	6.11e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—ovarian cancer	6.06e-06	3.97e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A1—ovarian cancer	6.06e-06	3.97e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—ovarian cancer	6.05e-06	3.97e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—ovarian cancer	6e-06	3.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—ovarian cancer	5.95e-06	3.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—ovarian cancer	5.93e-06	3.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	5.91e-06	3.87e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—ovarian cancer	5.89e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—ovarian cancer	5.88e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.88e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK3—ovarian cancer	5.85e-06	3.84e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—ovarian cancer	5.85e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1B1—ovarian cancer	5.81e-06	3.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—ovarian cancer	5.78e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—ovarian cancer	5.61e-06	3.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—ovarian cancer	5.6e-06	3.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—ovarian cancer	5.59e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK1—ovarian cancer	5.57e-06	3.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—ovarian cancer	5.57e-06	3.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—ovarian cancer	5.49e-06	3.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—ovarian cancer	5.45e-06	3.57e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMS—ovarian cancer	5.39e-06	3.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—ovarian cancer	5.37e-06	3.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK3—ovarian cancer	5.35e-06	3.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—ovarian cancer	5.28e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—ovarian cancer	5.28e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—ovarian cancer	5.26e-06	3.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—ovarian cancer	5.23e-06	3.43e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—ovarian cancer	5.22e-06	3.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—ovarian cancer	5.22e-06	3.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—ovarian cancer	5.17e-06	3.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—ovarian cancer	5.16e-06	3.38e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPP2R1A—ovarian cancer	5.15e-06	3.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK1—ovarian cancer	5.09e-06	3.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—ovarian cancer	5.09e-06	3.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK3—ovarian cancer	5e-06	3.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK3—ovarian cancer	4.94e-06	3.24e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—ovarian cancer	4.89e-06	3.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—ovarian cancer	4.86e-06	3.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—ovarian cancer	4.83e-06	3.17e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—YAP1—ovarian cancer	4.82e-06	3.16e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—ovarian cancer	4.81e-06	3.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—ovarian cancer	4.81e-06	3.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—ovarian cancer	4.8e-06	3.15e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—ovarian cancer	4.79e-06	3.14e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK1—ovarian cancer	4.76e-06	3.12e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—ovarian cancer	4.76e-06	3.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—ovarian cancer	4.75e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK1—ovarian cancer	4.7e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—ovarian cancer	4.7e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMS—ovarian cancer	4.7e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—ovarian cancer	4.68e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—ovarian cancer	4.68e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—ovarian cancer	4.56e-06	2.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—ovarian cancer	4.5e-06	2.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—ovarian cancer	4.49e-06	2.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—ovarian cancer	4.47e-06	2.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—ovarian cancer	4.44e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—ovarian cancer	4.42e-06	2.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—ovarian cancer	4.4e-06	2.88e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAV1—ovarian cancer	4.34e-06	2.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—ovarian cancer	4.31e-06	2.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—ovarian cancer	4.3e-06	2.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—ovarian cancer	4.28e-06	2.81e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—ovarian cancer	4.22e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—ovarian cancer	4.19e-06	2.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—ovarian cancer	4.15e-06	2.72e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.15e-06	2.72e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—ovarian cancer	4.13e-06	2.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—ovarian cancer	4.09e-06	2.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—ovarian cancer	4.08e-06	2.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—ovarian cancer	4.07e-06	2.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—ovarian cancer	4.05e-06	2.65e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—ovarian cancer	3.99e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	3.96e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—ovarian cancer	3.95e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FASN—ovarian cancer	3.93e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—ovarian cancer	3.91e-06	2.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—ovarian cancer	3.91e-06	2.56e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.86e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—ovarian cancer	3.82e-06	2.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAV1—ovarian cancer	3.79e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—ovarian cancer	3.77e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.73e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—ovarian cancer	3.66e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—ovarian cancer	3.65e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—ovarian cancer	3.62e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—ovarian cancer	3.61e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—ovarian cancer	3.61e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—ovarian cancer	3.61e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.58e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	3.48e-06	2.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK3—ovarian cancer	3.46e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—ovarian cancer	3.45e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—ovarian cancer	3.37e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—ovarian cancer	3.36e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—ovarian cancer	3.33e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK1—ovarian cancer	3.29e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—ovarian cancer	3.29e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—ovarian cancer	3.22e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.17e-06	2.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—ovarian cancer	3.11e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	3.03e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.03e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—ovarian cancer	2.98e-06	1.95e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.95e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMS—ovarian cancer	2.89e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—ovarian cancer	2.86e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—ovarian cancer	2.76e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—ovarian cancer	2.64e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.64e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—ovarian cancer	2.63e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—ovarian cancer	2.62e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—ovarian cancer	2.53e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—ovarian cancer	2.43e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—ovarian cancer	2.33e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAV1—ovarian cancer	2.33e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—ovarian cancer	2.28e-06	1.5e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.12e-06	1.39e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.87e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.85e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.63e-06	1.07e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.61e-06	1.06e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—ovarian cancer	1.51e-06	9.9e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—ovarian cancer	1.41e-06	9.22e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—ovarian cancer	1.32e-06	8.62e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	9.92e-07	6.5e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—ovarian cancer	8.11e-07	5.31e-06	CbGpPWpGaD
